peter attia on semaglutide 184 - AMA #29: GLP-1 Agonists - The Future of Treating Obesity? New insights on GLP-1 agonists—Ozempic,

With this risk posing a significant barrier to successful treatment, its crucial that GLP-1 medications are incorporated into a holistic wellness strategy to ensure their lasting effectiveness

Elkjaer ML, Frisch T, Reynolds R et al (2019a) Molecular signature of different lesion types in the brain white matter of patients with progressive multiple sclerosis

Many dominant genera in human intestines can produce secondary bile acids, of which Clostridium is the most active

Results Patient Disposition and Baseline Characteristics In total, 2836 patients receiving oral semaglutide 14 mg/flexibly dosed or comparators were included in the background medication subgroup analyses, and 365 patients receiving oral semaglutide 14 mg or placebo in PIONEER 8 were included in the insulin regimen subgroup analysis

Slower repair

Supports DNA synthesis and red blood cell formation